| Katie Godwin, BA, BS, LCDP | |
|
2 Old County Rd, Barrington, RI 02806-1600 | |
| (401) 246-1195 | |
| Not Available |
| Full Name | Katie Godwin |
|---|---|
| Gender | Female |
| Speciality | Counselor - Addiction (substance Use Disorder) |
| Location | 2 Old County Rd, Barrington, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639677818 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | CDP00722 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Katie Godwin, BA, BS, LCDP 2 Old County Rd, Barrington, RI 02806-1600 Ph: () - | Katie Godwin, BA, BS, LCDP 2 Old County Rd, Barrington, RI 02806-1600 Ph: (401) 246-1195 |
News Archive
Severe inflammatory response syndrome, or SIRS, occurs when the body's response to an overwhelming infection becomes uncontrolled. The very immune response meant to clear the pathogen and its toxins actually causes damage to the host's own tissues when it goes into overdrive, releasing too many immune signals.
Impax Laboratories, Inc. today confirms that Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol (tolterodine tartrate) immediate-release, 1 mg and 2 mg tablets.
Medtronic, Inc. announced that data from a multicenter, prospective, randomized, blinded, feasibility trial published today show promise for occipital nerve stimulation for treating medically refractory chronic migraines and support the need for further controlled study of the treatment. The study, called Occipital Nerve Stimulation for the Treatment of Intractable Migraine, included severely debilitated patients who had regularly experienced 15 or more headache days per month that were not responsive to currently available medical therapies.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 9 days ago
Susanna M Philibert, LICSW, LCDP Counselor Medicare: Accepting Medicare Assignments Practice Location: East Bay Mental Health Center, 2 Old County Road, Barrington, RI 02806 Phone: 401-246-1195 | |
Ms. Hollis Vale Burkhart, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 60 Bay Spring Ave., Pathways Wellness Center Suite B1, Barrington, RI 02806 Phone: 401-246-0214 | |
Nanci Adams, LMHC, ATR Counselor Medicare: Not Enrolled in Medicare Practice Location: 181 Rumstick Rd, Barrington, RI 02806 Phone: 401-487-8966 | |
Lori D Wright, MA Counselor Medicare: Not Enrolled in Medicare Practice Location: 2 Old County Road, Barrington, RI 02806 Phone: 401-246-1195 | |
Leanne Craven, LICSW, LCDP Counselor Medicare: Accepting Medicare Assignments Practice Location: 2 Old County Rd, Barrington, RI 02806 Phone: 401-246-1195 | |
Kylee Boles-reed, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 47 Wood Ave, Suite 2, Barrington, RI 02806 Phone: 401-552-5868 | |
Wunesh Woldeselassie Bairu, LMHC Counselor Medicare: Medicare Enrolled Practice Location: 60 Bay Spring Ave Unit B1, Barrington, RI 02806 Phone: 401-246-0214 |